Nonsurgical treatments
Orthobiologic, Stem-Cell, and Peptide Treatments
Selected nonsurgical options for appropriately evaluated orthopedic conditions — offered after individual medical evaluation and honest discussion of the evidence.
What These Treatments Are
Orthobiologic and peptide-based treatments are nonsurgical options considered for selected musculoskeletal conditions. They are not a single category of treatment — platelet-rich plasma (PRP), cellular products, and peptide therapies are distinct treatment types with different mechanisms, evidence bases, and regulatory considerations. They must not be treated as interchangeable.
These treatments are offered only after a thorough individual medical evaluation. Dr. Blythe will explain the available evidence, limitations, alternatives, regulatory status, expected cost, and whether a structural treatment may be more appropriate for your condition.
Patient Evaluation
Determining whether an orthobiologic or peptide-based treatment is medically reasonable for your condition requires a comprehensive evaluation. This may include:
- Medical history and symptom review
- Physical examination
- Review of imaging (MRI, CT, X-ray)
- Prior treatment response
- Medication and medical-risk review
- Identification of the actual pain generator
- Discussion of treatment goals
- Review of evidence, limitations, alternatives, and cost
Conditions Considered
Broad categories of conditions that may be considered for orthobiologic or peptide-based treatment include the following. Specific indications are determined individually at the time of evaluation.
- Selected tendon and ligament conditions
- Selected arthritic or degenerative joint conditions
- Selected musculoskeletal injuries
- Other orthopedic conditions considered individually
These treatments do not rebuild spinal discs, reverse advanced arthritis, repair complete tendon tears, or eliminate the need for surgery in every case.
Available Treatment Categories
Platelet-Rich Plasma (PRP)
PRP is prepared from the patient's own blood. A sample is processed to concentrate platelets, which are then injected into the target tissue. PRP is considered for selected tendon, joint, and soft-tissue conditions. Evidence and outcomes vary by diagnosis, preparation method, and patient factors. PRP is not a substitute for structurally necessary surgery.
Stem-Cell and Cellular Treatments
Cellular treatments involve the use of biologic material intended to support tissue healing or reduce inflammation. Specific products, cellular sources, and preparation methods vary. Dr. Blythe will explain the specific treatment being considered, its evidence base, regulatory status, and whether it is appropriate for your diagnosis. Product-specific details are discussed at the time of evaluation.
Peptide-Based Therapies
Peptide-based therapies are a distinct category of treatment. Specific peptides, routes of administration, and intended indications vary. The regulatory status and evidence base differ among individual peptides and uses. Dr. Blythe will explain the specific therapy being considered, including whether it is approved, off-label, or investigational for your condition.
Limitations
These treatments are not appropriate for every patient or every diagnosis. They do not mechanically stabilize an unstable joint, decompress a compressed nerve, repair every complete tendon tear, replace severely damaged joint surfaces, or correct every structural problem requiring surgery.
Regulatory and Evidence Disclosure
The evidence, regulatory status, and accepted indications differ among specific orthobiologic, cellular, and peptide-based treatments. Some treatments or uses may be investigational or off-label. Dr. Blythe discusses the specific treatment, available evidence, potential benefits, limitations, risks, alternatives, and cost before treatment is selected.
Frequently Asked Questions
Frequently Asked Questions
- What are orthobiologic treatments?
- Orthobiologic treatments use biological substances — derived from the patient's own blood, bone marrow, or from processed donor tissue — to support healing in joints, tendons, and soft tissue. Examples include platelet-rich plasma (PRP), bone marrow aspirate concentrate (BMAC), and amniotic or umbilical cord-derived products. These are adjunct treatments evaluated on a case-by-case basis and are not cures for arthritis or structural damage.
- Are stem-cell treatments FDA-approved for orthopedic conditions?
- Most stem-cell and cellular orthobiologic products are not FDA-approved for specific orthopedic indications. PRP is prepared from the patient's own blood and is not subject to the same regulatory pathway as drugs. Amniotic and umbilical cord products are regulated as human cells, tissues, and cellular and tissue-based products (HCT/Ps) under 21 CFR Part 1271. Dr. Blythe reviews the regulatory status of each product with patients before proceeding.
- Who is a candidate for orthobiologic treatment?
- Candidacy is determined after individual evaluation, review of imaging, and discussion of the diagnosis and treatment goals. Orthobiologics may be considered for patients with early to moderate joint degeneration, tendon injuries, or soft-tissue conditions who have not responded adequately to conservative treatment and are not yet candidates for surgery.
- Can orthobiologic injections replace surgery?
- No. Orthobiologic injections do not repair torn tendons, remove disc herniations, decompress nerves, or replace arthritic joints. They may reduce symptoms or improve the local biologic environment in selected cases, but they do not correct structural problems that require surgical repair. Dr. Blythe is direct about what these treatments can and cannot accomplish.
Schedule an Evaluation
An evaluation is required to determine whether an orthobiologic, stem-cell, or peptide-based treatment is medically reasonable for your condition. Dr. Blythe will explain the available evidence, limitations, alternatives, and whether a structural treatment may be more appropriate.